(Q38397719)

English

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

retracted scientific article published on April 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

cardiovascular disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Björn Dahlöf

0 references

author name string

Seibu Mochizuki

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Mitsuyuki Shimizu

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Katsunori Ikewaki

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Makoto Yoshikawa

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Ikuo Taniguchi

6

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Makoto Ohta

7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Taku Yamada

8

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Kazuhiko Ogawa

9

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Kiyoshi Kanae

10

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Makoto Kawai

11

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Shingo Seki

12

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Fumiko Okazaki

13

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Masayuki Taniguchi

14

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Satoru Yoshida

15

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Naoko Tajima

16

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Jikei Heart Study group

17

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

language of work or name

0 references

publication date

1 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

369

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

9571

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1431-1439

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The cellular and molecular response of cardiac myocytes to mechanical stress.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960669-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)60669-2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38397719&oldid=1940127115"